Drug Profile
NC 318
Alternative Names: NC-318Latest Information Update: 14 Sep 2023
Price :
$50
*
At a glance
- Originator Yale University School of Medicine
- Developer Emory University; Merck Sharp & Dohme; National Cancer Institute (USA); NextCure; Yale University School of Medicine
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Leukaemia; Non-small cell lung cancer; Solid tumours
Most Recent Events
- 12 Sep 2023 Efficacy and adverse event data from phase II trial in Non-small cell lung cancer released by NextCure
- 09 Sep 2023 Updated Efficacy data from a phase II trial in Non-small cell lung cancer presented at the 24th World Conference on Lung Cancer, 2023 (WCLC-2023)
- 04 Apr 2023 NextCure completes a phase-I/II trial in Solid tumours in USA (IV) (NCT03665285)